Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Heike Pfeifer, Fabian Lang, Walter Fiedler, Matthias Stelljes, Folker Schneller, Björn Steffen, Boris Böll, Andreas Viardot, Christoph Faul, Lino L. Teichmann, Hendrik Poeck, Joerg Westermann, Kerstin Schäfer-Eckart, Thomas Heinicke, Thomas Burmeister, Stefan Schwartz, Monika Brueggemann, Hubert Serve, Nicola Goekbuget

Blood (2024) 144 (Supplement 1): 840.

https://doi.org/10.1182/blood-2024-201217

Published: 2024

Journal Articles

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Blood (2024) 143 (14): 1391–1398.

https://doi.org/10.1182/blood.2023021752

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

Blood (2023) 142 (Supplement 1): 843.

https://doi.org/10.1182/blood-2023-187315

Published: 2023

Journal Articles

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Blood (2021) 138 (Supplement 1): 362.

https://doi.org/10.1182/blood-2021-146306

Published: 2021

Journal Articles

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Blood (2018) 132 (Supplement 1): 31.

https://doi.org/10.1182/blood-2018-99-114552

Published: 2018

Journal Articles

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

Blood (2018) 131 (13): 1464–1475.

https://doi.org/10.1182/blood-2017-07-796862

Published: 2018

Includes: Supplemental data

Journal Articles

Hematopoietic stem cell involvement in BCR-ABL1– positive ALL as a potential mechanism of resistance to blinatumomab therapy

Inga Nagel, Marius Bartels, Johannes Duell, Hans-Heinrich Oberg, Sandra Ussat, Henrike Bruckmueller, Oliver Ottmann, Heike Pfeifer, Heiko Trautmann, Nicola Gökbuget, Almuth Caliebe, Dieter Kabelitz, Michael Kneba, Heinz-August Horst, Dieter Hoelzer, Max S. Topp, Ingolf Cascorbi, Reiner Siebert, Monika Brüggemann

Blood (2017) 130 (18): 2027–2031.

https://doi.org/10.1182/blood-2017-05-782888

Published: 2017

Includes: Supplemental data

Journal Articles

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Blood (2016) 128 (6): 774–782.

https://doi.org/10.1182/blood-2016-02-700153

Published: 2016

Includes: Supplemental data

Journal Articles

Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02)

Blood (2014) 124 (21): 798.

https://doi.org/10.1182/blood.V124.21.798.798

Published: 2014

Journal Articles

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

Lydia Wunderle, MD, Susanne Badura, Fabian Lang, MD, Andrea Wolf, Eberhard Schleyer, MD, Hubert Serve, MD, Nicola Goekbuget, MD, Heike Pfeifer, MD, Gesine Bug, MD, PhD, Oliver G. Ottmann, MD

Blood (2013) 122 (21): 2675.

https://doi.org/10.1182/blood.V122.21.2675.2675

Published: 2013

Journal Articles

Subclonal IKZF1 Deletions Indicate a Multiclonal Evolution In BCR-ABL1-Positive B-Cell Precursor ALL

Verena Boehm, PhD, Annett Lebenatus, Marius Bartels, Inga Nagel, PhD, Heiko Trautmann, PhD, Nicola Gökbuget, MD, Dieter Hoelzer, MD, Heike Pfeifer, MD, Reiner Siebert, MD, Michael Kneba, MD, Oliver Ottmann, MD, Monika Brüggemann, MD

Blood (2013) 122 (21): 1327.

https://doi.org/10.1182/blood.V122.21.1327.1327

Published: 2013

Journal Articles

In Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, The Negative Prognostic Impact Of IKZF1, CDKN2A/B and PAX5 Deletions Is Not Abrogated By Allogeneic Stem Cell Transplantation In First Complete Remission

Heike Pfeifer, MD, Katharina Raum, Sandra Markovic, Stephanie Fey, Julia Obländer, Verena Nowak, Wunderle Lydia, MD, Fabian Lang, MD, Dieter Hoelzer, MD, Wolf-Karsten Hofmann, MD, Nicola Goekbuget, MD, Oliver G. Ottmann, MD, Daniel Nowak, MD

Blood (2013) 122 (21): 231.

https://doi.org/10.1182/blood.V122.21.231.231

Published: 2013

Journal Articles

Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Heike Pfeifer, MD, Sylvia Wystub, PhD, A. Binckebanck, Barbara Wassmann, Andreas Käbisch, Michael Lübbert, MD, Lothar Leimer, MD, Aristoteles Giagounidis, MD, Winfried Gassmann, MD, PhD, Patrick Brueck, MD, Hubert Serve, Prof. Dr. med., Dieter Hoelzer, MD, Oliver G. Ottmann, MD

Blood (2012) 120 (21): 1503.

https://doi.org/10.1182/blood.V120.21.1503.1503

Published: 2012

Journal Articles

Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.

Blood (2012) 120 (21): 2608.

https://doi.org/10.1182/blood.V120.21.2608.2608

Published: 2012

Journal Articles

Prominin-1/CD133 Is Involved in the Lineage Decision As Well As a in the Sensitivity to Molecular Therapy in Ph+ Acute Lymphatic Leukemia.

Anna T. Metodieva, Heike Pfeifer, MD, Afsar Mian, PhD, Anja Vogel, Hubert Serve, Prof. Dr. med., Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2012) 120 (21): 2579.

https://doi.org/10.1182/blood.V120.21.2579.2579

Published: 2012

Journal Articles

The Reciprocal t(9;22) p96 ABL/BCR fusion Protein Eenhances the Transformation Potential of BCR/ABL and Increases Therapy Resistance in Models of Ph+ Acute Lymphatic Leukemia

Anahita Rafiei, Afsar Mian, PhD, Anna Metodieva, Claudia Oancea, Hubert Serve, MD, Heike Pfeifer, MD, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2012) 120 (21): 3539.

https://doi.org/10.1182/blood.V120.21.3539.3539

Published: 2012

Journal Articles

Global Phosphoproteome Analysis of AML Bone Marrow Reveals Predictive Markers for the Treatment with AC220

Christoph Schaab, Dr., Felix Oppermann, Dr., Heike Pfeifer, Dr. med., Martin Klammer, Dr., Andreas Tebbe, Dr., Thomas Oellerich, Dr. med., Jürgen Krauter, Prof. Dr. med., Mark J. Levis, MD, PhD, Alexander E Perl, MD, Henrik Daub, Dr., Björn Steffen, MD, Klaus Godl, Dr., Hubert Serve, Prof. Dr. med.

Blood (2012) 120 (21): 786.

https://doi.org/10.1182/blood.V120.21.786.786

Published: 2012

Journal Articles

International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia

Blood (2011) 118 (21): 2535.

https://doi.org/10.1182/blood.V118.21.2535.2535

Published: 2011

Journal Articles

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Blood (2011) 118 (21): 247.

https://doi.org/10.1182/blood.V118.21.247.247

Published: 2011

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

NARROW

Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

Hematopoietic stem cell involvement in BCR-ABL1– positive ALL as a potential mechanism of resistance to blinatumomab therapy

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02)

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

Subclonal IKZF1 Deletions Indicate a Multiclonal Evolution In BCR-ABL1-Positive B-Cell Precursor ALL

In Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, The Negative Prognostic Impact Of IKZF1, CDKN2A/B and PAX5 Deletions Is Not Abrogated By Allogeneic Stem Cell Transplantation In First Complete Remission

Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.

Prominin-1/CD133 Is Involved in the Lineage Decision As Well As a in the Sensitivity to Molecular Therapy in Ph+ Acute Lymphatic Leukemia.

The Reciprocal t(9;22) p96 ABL/BCR fusion Protein Eenhances the Transformation Potential of BCR/ABL and Increases Therapy Resistance in Models of Ph+ Acute Lymphatic Leukemia

Global Phosphoproteome Analysis of AML Bone Marrow Reveals Predictive Markers for the Treatment with AC220

International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only